ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Sunday, October 17, 2010

ECTRIMS: No Benefit from Adding Statin in Early MS

This report is part of a 12-month Clinical Context series.


By Richard Robinson, Contributing Writer, MedPage Today
Published: October 16, 2010
Reviewed by Michael J. Olek, DO; Director, Newport Doctors Multiple Sclerosis Clinic.




GOTHENBURG, Sweden -- Adjunctive simvastatin provided no benefit in multiple sclerosis patients taking intramuscular interferon beta-1a (Avonex), results of a new study showed.
 
 
"The study gave a clear result that simvastatin cannot be recommended as an add-on therapy for intramuscular interferon beta-1A," according to Per Soelberg Sorensen, MD, of Copenhagen University Hospital in Denmark.
 
 
But while simvastatin offered no additional disease control compared with placebo, it was safe, Soelberg Sorensen said at the European Committee for Treatment and Research in Multiple Sclerosis meeting.
 
 
"We know that statins have immunomodulatory properties" he said, and in a small open trial, simvastatin reduced gadolinium-enhancing lesions in MS.
However, a small trial of atorvastatin as combination therapy in MS indicated it might reduce the effect of subcutaneous interferon beta-1a.



***********************************************************
"Providing You with 'MS Views and News', is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Posted by at
Reactions: 

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)